Patents Examined by Regina M. DeBerry
  • Long-acting polypeptides and methods of producing same
    Patent number: 10030060
    Abstract: A polypeptide and polynucleotides encoding same comprising one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to an amino terminus of a cytokine and two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a carboxy terminus of a cytokine are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: July 24, 2018
    Assignee: OPKO Biologics Ltd.
    Inventors: Fuad Fares, Udi Eyal Fima
  • Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
    Patent number: 10010583
    Abstract: The described invention provides methods for treating an inflammatory brain disease, disorder or condition and for treating a traumatic brain injury having an inflammatory component in a subject in need thereof using isolated erythropoietin (EPO)-derived oligopeptides.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: July 3, 2018
    Inventors: Bo Wang, Rui R. Yuan, Wei Lu, Peter Dowling
  • Methods for purifying erythropoietin analogs having lower isoelectric point
    Patent number: 9994627
    Abstract: The present invention relates to a method for purifying an erythropoietin analog having a low isoelectric point below 4 by adding an N-linked sugar chain with high purity. In accordance with the present invention, the erythropoietin analog having an isoelectric point below 4, which is an isoform having more sialic acid residues, can be effectively purified via three-step chromatographic processes in short time at lower cost.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: June 12, 2018
    Assignee: CHONG KUN DANG PHARMACEUTICAL CORP.
    Inventors: Yeo-Wook Koh, Sang-Yong Lee, Cook-Hee Kim, Seung-Hui Lee, Ha-Na Kim, Su-Yon Kim, Jin-Hyun Seong, Yong-Hyun Cho
  • Erythropoietin variants
    Patent number: 9988427
    Abstract: The present invention relates to novel endogenous variants of erythropoietin (EPO) and their use for treatment or prevention of a condition associated with tissue damage due to cell death (apoptosis, necrosis) and inflammation, in particular for neuroprotection, e.g. treatment of acute (for example stroke) and chronic disease (for example ALS) of the nervous system.
    Type: Grant
    Filed: December 15, 2008
    Date of Patent: June 5, 2018
    Assignee: CHARITE UNIVERSITAETSMEDIZEN-BERLIN
    Inventors: Andreas Meisel, Josef Priller, Christel Bonnas, Ulrich Dirnagl
  • Long-acting polypeptides and methods of producing and administering same
    Patent number: 9975938
    Abstract: A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: May 22, 2018
    Assignee: OPKO Biologics Ltd.
    Inventors: Fuad Fares, Udi Eyal Fima
  • Composition for aiding surgical procedures for treating ischemic vascular diseases
    Patent number: 9956265
    Abstract: The present invention relates to a composition comprising erythropoietin (EPO) as an active ingredient for aiding surgical procedures for treating ischemic vascular diseases. The present invention also relates to a method for treating ischemic vascular diseases using a combination of the composition and the invasive procedure for sufficient disruption of the physical barriers for new neovascularization. The composition for aiding surgical or invasive procedures according to the present invention would be beneficial for the success rate and safety issue of a variety of surgical procedures such as minimally invasive operations performed on a patient suffering from a variety of cerebral ischemic vascular diseases including ischemic stroke and moyamoya disease, and can be widely used in the treatment of a variety of ischemic vasculopathies in cardiac or peripheral artery system.
    Type: Grant
    Filed: April 26, 2012
    Date of Patent: May 1, 2018
    Assignee: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventor: Ji Man Hong
  • Anti-CCL17 antibodies
    Patent number: 9944697
    Abstract: The present invention relates to antibodies specifically binding CCL17, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: April 17, 2018
    Assignee: JANSSON BIOTECH, INC.
    Inventors: Ken Boakye, Alfred Del Vecchio, John Kehoe, Eilyn Lacy, Lynne Murray, Mary Ryan, Sandra Santulli-Marotto, John Wheeler, Brian Whitaker, Alexey Teplyakov
  • Enhanced erythropoiesis and iron metabolism
    Patent number: 9920011
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erythropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Grant
    Filed: November 19, 2013
    Date of Patent: March 20, 2018
    Assignee: FibroGen, Inc.
    Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Robert C. Stephenson, Todd W. Seeley, Ingrid Langsetmo Parobok
  • Long-acting polypeptides and methods of producing and administering same
    Patent number: 9908924
    Abstract: A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also discarded.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: March 6, 2018
    Assignee: OPKO Biologics Ltd.
    Inventors: Fuad Fares, Udi Eyal Fima
  • Long-acting polypeptides and methods of producing same
    Patent number: 9896494
    Abstract: A polypeptide and polynucleotides encoding same comprising one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to an amino terminus of a cytokine and two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a carboxy terminus of a cytokine are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: February 20, 2018
    Assignee: OPKO Biologics Ltd.
    Inventors: Fuad Fares, Udi Eyal Fima
  • Long-acting polypeptides and methods of producing and administering same
    Patent number: 9884901
    Abstract: A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: February 6, 2018
    Assignee: OPKO Biologics Ltd.
    Inventors: Fuad Fares, Udi Eyal Fima
  • Stable formulations of polypeptides and uses thereof
    Patent number: 9884117
    Abstract: Stable formulations are provided that contain immunoglobulin single variable domains at a high concentration. The formulations are useful as pharmaceutical formulation and suitable for subcutaneous administration. The formulations can be transported and stored under various stress conditions. The invention further relates to containers and pharmaceutical units comprising such formulations and to methods for preparing and prophylactic and therapeutic uses of the formulations and pharmaceutical units of the invention.
    Type: Grant
    Filed: September 3, 2010
    Date of Patent: February 6, 2018
    Assignee: Ablynx N.V.
    Inventors: Ann Brige, Christine Labeur, Marc Jozef Lauwereys
  • Peptide and application thereof
    Patent number: 9856304
    Abstract: Provided are a new peptide, a vector inserting a DNA that codes said peptide, a transformant obtained by transformation with that vector, and applications of said peptide, vector and transformant. The peptide comprises an amino acid sequence set forth in SEQ ID NO: 1, or an amino acid sequence obtained by substituting, deleting or adding one or more amino acids to/from the amino acid sequence set forth in SEQ ID NO: 1. This peptide and the vector inserting a DNA that codes this peptide are suitable for use in an agent for promoting the proliferation of pancreatic hormone-producing cells, or a differentiation induction promoter that induces differentiation to pancreatic hormone-producing cells.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: January 2, 2018
    Assignee: SAITAMA MEDICAL UNIVERSITY
    Inventors: Hideo Toyoshima, Yasushi Okazaki, Tomotaka Yokoo, Izumi Sugahara
  • Long-acting polypeptides and methods of producing and administering same
    Patent number: 9828417
    Abstract: A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: November 28, 2017
    Assignee: OPKO Biologics Ltd.
    Inventors: Udi Eyal Fima, Gili Hart
  • Post procedure skin care gel and methods of use thereof
    Patent number: 9808654
    Abstract: Compositions and methods are provided for a post-procedure care following the treatment of skin with cosmetic skin resurfacing treatments, which include without limitation a variety of laser treatments, chemical peeling and dermabrasion, by applying a silicone-based gel formulation in combination with therapeutic peptides. Peptides of interest include one or more of transforming growth factor, epidermal growth factor, and basic fibroblast growth factor. The formulation may further comprise an effective dose of one or more acylated peptides, which peptides are active in remodeling of the skin.
    Type: Grant
    Filed: February 11, 2013
    Date of Patent: November 7, 2017
    Assignee: JAN MARINI SKIN RESEARCH
    Inventors: Jan Marini, Subhash J. Saxena
  • Compounds and methods for modulating pharmacokinetics
    Patent number: 9790264
    Abstract: Methods and compositions are described for management of the pharmacokinetic properties of active agents, e.g., therapeutic moieties, by conjugating, fusing, or non-direct linkage of the active agent to one or more wild-type or modified heparin-binding peptides (HB). Compounds may be administered to tissues including skin. Contemplated uses include treatment of disease, allergen immunotherapy, and immunization. Other aspects relate to compositions, methods and kits comprising heparin-binding peptides (HB) fused or conjugated to the therapeutic agents.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: October 17, 2017
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Richard T. Lee, Parth Patwari, James Pancoast
  • GIP receptor-active glucagon compounds
    Patent number: 9790263
    Abstract: Glucagon peptides with increased GIP activity are provided, optionally with GLP-1 and/or glucagon activity. In some embodiments, C-terminally extended glucagon peptides comprising an amino acid sequence substantially similar to native glucagon are provided herein.
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: October 17, 2017
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. DiMarchi, Tao Ma
  • Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
    Patent number: 9765128
    Abstract: The present invention provides isolated stabilized EPO-derived peptides and their mimics that protect against tissue damage in subjects having diverse forms of neural and non-neural organ system injury, pharmaceutical compositions containing the isolated stabilized EPO-derived peptides, methods for treating symptoms of a disease, disorder or condition having an inflammatory or an autoimmune component in a subject in need thereof, and methods for downregulating immune mediator activity in a subject in need thereof.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: September 19, 2017
    Inventor: Peter C. Dowling
  • Anti-big-endothelin-1 (big-ET-1) antibodies and uses thereof
    Patent number: 9751932
    Abstract: The present invention provides antibodies that bind big-endothelin-1 (“big-ET-1”), and methods of using same. According to certain embodiments of the invention, the antibodies specifically bind human big-ET-1 but do not bind human small-ET-1 (i.e., the active form of endothelin-1 that results from proteolytic cleavage of big-ET-1 by endothelin-converting enzyme-1 [ECE-1]). According to certain embodiments of the invention, the anti-big-ET-1 antibodies are capable of blocking cleavage of big-ET-1 by ECE-1. The antibodies of the invention are useful for the treatment of big-ET-1-related disorders, including hypertension disorders, fibrotic disorders, neurodegenerative disorders, retinal disorders, pain and cancers.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: September 5, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lori C. Morton, Douglas MacDonald
  • Antibodies that bind IL-4 and/or IL-13 and their uses
    Patent number: 9738728
    Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: August 22, 2017
    Assignee: Sanofi
    Inventors: Ercole Rao, Vincent Mikol, Danxi Li, Jochen Kruip, Matthew Davison